The U.S. Food and Drug Administration (FDA) has granted traditional approval to Novartis for Fabhalta (iptacopan), a groundbreaking oral Factor B inhibitor designed to slow the progression of kidney function decline in adults diagnosed with primary immunoglobulin A nephropathy (IgAN) who are at significant risk of disease advancement. This pivotal approval marks a significant milestone, transitioning Fabhalta from its initial accelerated approval in August 2024, which focused on reducing proteinuria, to a comprehensive indication for preserving kidney health in this challenging autoimmune condition. The traditional approval was robustly supported by compelling data from the pivotal Phase III APPLAUSE-IgAN study, underscoring the drug’s efficacy and safety profile.
A New Era in IgAN Management
Primary IgA nephropathy (IgAN) is recognized as one of the most prevalent autoimmune kidney diseases globally, affecting an estimated 25 individuals per million population annually. It is characterized by the deposition of IgA antibodies in the glomeruli, leading to inflammation and progressive damage to the kidneys. Without effective intervention, IgAN can lead to a substantial decline in kidney function, ultimately necessitating dialysis or kidney transplantation for a significant proportion of affected individuals. The therapeutic landscape for IgAN has historically been limited, with treatments primarily focusing on supportive care and immunosuppression, often with variable success and considerable side effects.
The FDA’s decision to grant traditional approval to Fabhalta signifies a major advancement, offering a targeted therapy that addresses the underlying complement-mediated inflammation characteristic of IgAN. This approval pathway, which replaces accelerated approval, indicates that the FDA has reviewed and confirmed the clinical benefit of the drug based on comprehensive data, moving beyond surrogate endpoints like proteinuria reduction to a more direct measure of clinical outcome – slowing the decline of kidney function.
The Pivotal APPLAUSE-IgAN Study: Evidence of Efficacy
The traditional approval of Fabhalta is directly attributed to the robust findings of the Phase III APPLAUSE-IgAN study. This large-scale, multi-center, randomized, double-blind, placebo-controlled trial enrolled adult patients with primary IgAN who exhibited indicators of disease progression, such as proteinuria and reduced estimated glomerular filtration rate (eGFR). The study was designed to rigorously assess the efficacy and safety of Fabhalta over a two-year treatment period.
The primary endpoint of the APPLAUSE-IgAN study focused on the annualised mean rate of change in eGFR. The results were unequivocally positive, demonstrating a statistically significant and clinically meaningful difference between the Fabhalta treatment arm and the placebo arm. Patients receiving Fabhalta experienced a considerably slower decline in kidney function, with an annualised mean decrease in eGFR of -3.0 mL/min/1.73m² per year. In stark contrast, the placebo group exhibited a more rapid deterioration of kidney function, with an annualised mean decrease of -5.7 mL/min/1.73m² per year. This represents nearly a doubling of the rate of kidney function loss in the placebo group compared to those treated with Fabhalta, highlighting the drug’s substantial renoprotective effect.
Beyond the primary endpoint, Fabhalta demonstrated consistent benefits across a range of important kidney health measures. These included significant reductions in proteinuria (measured as urine protein-to-creatinine ratio, uPCR), which was the basis for the earlier accelerated approval, as well as improvements in markers of inflammation and kidney damage. The consistent positive outcomes across multiple endpoints provide a comprehensive picture of Fabhalta’s efficacy in addressing the multifaceted pathology of IgAN.
Safety Profile and Risk Mitigation
The safety and tolerability of Fabhalta were thoroughly evaluated throughout the APPLAUSE-IgAN study. The observed safety profile was found to be consistent with previously reported findings from earlier clinical trials. The most frequently reported adverse events in patients treated with Fabhalta included abdominal pain, dizziness, and nausea. These adverse events were generally mild to moderate in severity and manageable.
However, as with many potent immunomodulatory therapies, Fabhalta carries a potential risk of serious infections. Specifically, there is an elevated risk of serious infections from encapsulated bacteria. To mitigate this risk, the FDA has mandated that access to Fabhalta in the United States requires patient enrollment in a Risk Evaluation and Mitigation Strategy (REMS) program. This program emphasizes the importance of recommended vaccinations against encapsulated bacteria prior to initiating treatment with Fabhalta. Healthcare providers are instructed to ensure that patients are up-to-date on their vaccinations or receive the necessary immunizations before commencing therapy. This precautionary measure is crucial for safeguarding patients and optimizing the benefit-risk profile of Fabhalta.
Novartis’s Commitment and Patient Impact
Victor Bultó, Novartis U.S. President, expressed enthusiasm regarding the traditional approval, stating, "Today’s approval reinforces Fabhalta’s role in preserving kidney function by significantly slowing disease progression, an outcome that matters deeply to patients at risk of long-term kidney damage. This milestone underscores the importance of continued innovation for people living with IgAN and our commitment to addressing the underlying drivers of disease.” His statement emphasizes the profound impact this approval will have on patients’ lives, offering hope for a future with preserved kidney function and a reduced burden of end-stage renal disease.
Fabhalta’s mechanism of action as an oral Factor B inhibitor targeting the alternative complement pathway represents a novel therapeutic approach. The complement system is a critical component of the immune system, but its dysregulation, particularly the alternative pathway, plays a central role in the pathogenesis of IgAN. By inhibiting Factor B, Fabhalta effectively dampens this overactive inflammatory cascade, thereby protecting the kidneys from further damage.
Chronology of Approval and Regulatory Milestones
The journey of Fabhalta from development to traditional FDA approval has been marked by several key regulatory milestones:
- Initial Development and Pre-clinical Studies: Novartis invested significantly in understanding the role of the complement system in IgAN and developing iptacopan as a targeted therapeutic.
- Phase I and II Clinical Trials: Early-stage studies established the safety and initial efficacy signals of iptacopan in healthy volunteers and IgAN patients.
- Phase III APPLAUSE-IgAN Study Initiation: The pivotal trial commenced, designed to provide definitive evidence of efficacy and safety in a large patient population at risk of IgAN progression.
- Accelerated Approval (August 2024): The FDA granted accelerated approval for Fabhalta based on its demonstrated ability to reduce proteinuria, a surrogate endpoint that often predicts clinical benefit in kidney diseases. This allowed for earlier patient access while further confirmatory studies were underway.
- Submission for Traditional Approval: Following the positive completion of the APPLAUSE-IgAN study, Novartis submitted comprehensive data to the FDA seeking traditional approval.
- Traditional FDA Approval (Current Date): The FDA’s decision to grant traditional approval signifies a higher level of confidence in Fabhalta’s ability to slow the decline of kidney function, moving beyond proteinuria reduction.
This phased approach to approval is common for novel therapies, allowing for earlier access for patients while ensuring that robust clinical evidence is gathered to support long-term use.
Broader Implications and Future Outlook
The traditional approval of Fabhalta has far-reaching implications for the management of IgAN and the broader field of nephrology. It validates the complement system as a viable therapeutic target for IgAN and may pave the way for the development of other complement-inhibiting therapies. For patients, it offers a much-needed treatment option that directly addresses the underlying disease process, potentially altering the natural history of IgAN and improving long-term outcomes.
Furthermore, the success of Fabhalta highlights the increasing importance of personalized medicine in treating complex autoimmune diseases. By identifying patients at high risk of progression, clinicians can now offer a targeted therapy that has demonstrated a significant impact on slowing kidney function decline. This shift from a one-size-fits-all approach to a more nuanced, evidence-based strategy is crucial for optimizing patient care.
Novartis’s continued investment in research and development, as evidenced by their recent European Commission approval for Itvisma (onasemnogene abeparvovec) for spinal muscular atrophy, underscores their commitment to addressing unmet medical needs across a spectrum of rare and serious diseases. The success with Fabhalta in IgAN is a testament to this dedication and promises to reshape the treatment paradigm for kidney disease patients worldwide. The REMS program, while an important safety measure, will necessitate careful patient selection and management to ensure optimal access and adherence to treatment protocols. As Fabhalta becomes more widely adopted, ongoing pharmacovigilance and real-world data collection will be essential to further refine its use and monitor its long-term impact on the IgAN patient population.
